The landscape of diabetes care is changing with the emergence of GLP-1 patches . These novel patches offer a potentially less invasive alternative to injections for individuals managing diabetes 2. They deliver a GLP-1 agonist directly through the epidermis, circumventing the need for regular injections and possibly enhancing patient adherence . In